NEW YORK, March 05, 2018 -- Rosen Law Firm, a global investor rights law firm, announces that a lawsuit has been filed on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.
To join the Bellicum class action, go to http://rosenlegal.com/cases-1286.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with Bellicum’s lead product candidate, BPX-501; and (2) as a result, Bellicum’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1286.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


DeepSeek to Raise AI API Prices as Demand for New Models Surges
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 



